We use cookies to understand how you use our site and to improve the overall user experience. This includes personalizing content and advertising. Read our Privacy Policy
Foxy-5 has been used in trials studying the treatment of Prostate Cancer, Colorectal Cancer, Metastatic Colon Cancer, Metastatic Breast Cancer, and Metastatic Prostate Cancer.
CAT No: R1861
CAS No: 881188-51-8
Synonyms/Alias: FOXY-5;881188-51-8;FOXY5;Foxy 5;N-Formyl-Met-Asp-Gly-Cys-Glu-Leu;WNT-5A derived hexapeptide FOXY-5;CBZ9UL0ARB;UNII-CBZ9UL0ARB;L-Leucine,N-formyl-L-methionyl-L-a-aspartylglycyl-L-cysteinyl-L-a-glutamyl-;L-Leucine, N-formyl-L-methionyl-L-alpha-aspartylglycyl-L-cysteinyl-L-alpha-glutamyl-;(2S)-2-[[(2S)-4-carboxy-2-[[(2R)-2-[[2-[[(2S)-3-carboxy-2-[[(2S)-2-formamido-4-methylsulfanylbutanoyl]amino]propanoyl]amino]acetyl]amino]-3-sulfanylpropanoyl]amino]butanoyl]amino]-4-methylpentanoic acid;(2S,5S,8R,14S)-5-(2-carboxyethyl)-14-((S)-2-formamido-4-(methylthio)butanamido)-2-isobutyl-8-(mercaptomethyl)-4,7,10,13-tetraoxo-3,6,9,12-tetraazahexadecanedioic acid;L-LEUCINE, N-FORMYL-L-METHIONYL-L-.ALPHA.-ASPARTYLGLYCYL-L-CYSTEINYL-L-.ALPHA.-GLUTAMYL-;Wnt5a hexapeptide;(2S)-2-((2S)-4-carboxy-2-((2R)-2-(2-((2S)-3-carboxy-2-((2S)-2-formamido-4-(methylsulfanyl)butanamido)propanamido)acetamido)-3-sulfanylpropanamido)butanamido)-4-methylpentanoic acid;(2S)-2-[(2S)-4-carboxy-2-[(2R)-2-{2-[(2S)-3-carboxy-2-[(2S)-2-formamido-4-(methylsulfanyl)butanamido]propanamido]acetamido}-3-sulfanylpropanamido]butanamido]-4-methylpentanoic acid;Foxy 5 TFA;FOXY 5 [WHO-DD];FOXY-5 [WHO-DD];Foxy-5(Wnt5a peptide mimetic);CHEMBL4297281;SCHEMBL23477401;formyl-Met-Asp-Gly-Cys-Glu-Leu;Foxy-5(Wnt5a peptide mimetic)?;CHEBI:125492;Wnt-5a Mimic Hexapeptide Foxy-5;EX-A4066;HY-P1416;AKOS025147366;CCG-208076;DB13034;DA-73540;CS-0033287;NS00072887;BRD-K13005598-001-01-5;BRD-K13005598-001-02-3;Q27216112;
Quick InquiryCustom Peptide SynthesisPeptide Library Construction and Screening
Powerful screening tools in biological and chemical research
M.F/Formula | C26H42N6O12S2 |
M.W/Mr. | 694.8 |
Sequence | One Letter Code:MDGCEL Three Letter Code:For-Met-Asp-Gly-Cys-Glu-Leu-OH |
Purity | > 95% |
Activity | Wnt5a peptide mimetic. Impairs migration and invasion of 4T1 breast cancer cells in vitro. Also inhibits metastasis of inoculated 4T1 cells in mice. |
Source# | Synthetic |
Long-term Storage Conditions | Soluble to 1 mg/ml in PBS (pH 7.4); 10 mM in DMSO |
Shipping Condition | Wet ice in continental US; may vary elsewhere |
InChI | InChI=1S/C26H42N6O12S2/c1-13(2)8-17(26(43)44)32-24(41)15(4-5-20(35)36)30-25(42)18(11-45)29-19(34)10-27-22(39)16(9-21(37)38)31-23(40)14(28-12-33)6-7-46-3/h12-18,45H,4-11H2,1-3H3,(H,27,39)(H,28,33)(H,29,34)(H,30,42)(H,31,40)(H,32,41)(H,35,36)(H,37,38)(H,43,44)/t14-,15-,16-,17-,18-/m0/s1 |
InChI Key | WFZPJYYCTSHDJI-ATIWLJMLSA-N |
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at info@creative-peptides.com. We will endeavor to provide highly satisfying products and services.
USA
Address: SUITE 115, 17 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-624-4882
Fax: 1-631-614-7828
Email: info@creative-peptides.com
Germany
Address: Industriepark Höchst, Gebäude G830
65929 Frankfurt am Main
Email: info@creative-peptides.com